Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Tests a PET imaging agent in adults with advanced breast or lung cancer
Tests a PET scan agent, [68Ga]Ga-DWJ155, in adults with advanced breast or lung cancer.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 26 Jun 2026
- Expected to end
- 31 Oct 2028
- Type of study
- Interventional
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced breast cancer or advanced non-small cell lung cancer (NSCLC) to test an imaging agent, [68Ga]Ga-DWJ155.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced breast cancer or advanced NSCLC.
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Netherlands
- Pharmaceutical Research Associates Group B.V.Groningen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests a PET imaging agent in adults with advanced breast or lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 August 2026